An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
|Slideshows|August 21, 2017
The Human Epilepsy Project
Author(s)Jeffrey A. Loeb, MD, PhD
Dr. Loeb summarizes a global and one-of-a-kind approach of biomarker and drug discovery using systems biology of human brain tissues.
Advertisement
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis
4
Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy
5